42 related articles for article (PubMed ID: 15956643)
1. Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
Jabbour SK
J Clin Oncol; 2014 Dec; 32(34):3794-6. PubMed ID: 25349298
[No Abstract] [Full Text] [Related]
2. PDK1: a new therapeutic target for glioblastoma?
Velpula KK; Tsung AJ
CNS Oncol; 2014 May; 3(3):177-9. PubMed ID: 25055123
[No Abstract] [Full Text] [Related]
3. Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.
Bansal N; Mims J; Kuremsky JG; Olex AL; Zhao W; Yin L; Wani R; Qian J; Center B; Marrs GS; Porosnicu M; Fetrow JS; Tsang AW; Furdui CM
Antioxid Redox Signal; 2014 Jul; 21(2):221-36. PubMed ID: 24597745
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
5. When orthologs diverge between human and mouse.
Gharib WH; Robinson-Rechavi M
Brief Bioinform; 2011 Sep; 12(5):436-41. PubMed ID: 21677033
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
Kim YW; Liu TJ; Koul D; Tiao N; Feroze AH; Wang J; Powis G; Yung WK
Neuro Oncol; 2011 Apr; 13(4):367-75. PubMed ID: 21430111
[TBL] [Abstract][Full Text] [Related]
7. The GIST paradigm: lessons for other kinase-driven cancers.
Antonescu CR
J Pathol; 2011 Jan; 223(2):251-61. PubMed ID: 21125679
[TBL] [Abstract][Full Text] [Related]
8. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
Akazawa T; Kwatra SG; Goldsmith LE; Richardson MD; Cox EA; Sampson JH; Kwatra MM
J Neurochem; 2009 May; 109(4):1079-86. PubMed ID: 19519779
[TBL] [Abstract][Full Text] [Related]
9. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
10. Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Preusser M; Gelpi E; Rottenfusser A; Dieckmann K; Widhalm G; Dietrich W; Bertalanffy A; Prayer D; Hainfellner JA; Marosi C
J Neurooncol; 2008 Sep; 89(2):211-8. PubMed ID: 18458820
[TBL] [Abstract][Full Text] [Related]
11. Correlative studies in neuro-oncology trials: should they influence treatment?
Hegi ME; Stupp R
Curr Oncol Rep; 2006 Jan; 8(1):54-7. PubMed ID: 16464404
[TBL] [Abstract][Full Text] [Related]
12. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
13. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
de Braud F; De Pas T; Spaggiari L; Veronesi G; Curigliano G; Noberasco C; Pelosi G
J Natl Cancer Inst; 2005 Mar; 97(6):461-2; author reply 462-3. PubMed ID: 15770011
[No Abstract] [Full Text] [Related]
14. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib hydrochloride.
Minna JD; Dowell J
Nat Rev Drug Discov; 2005 May; Suppl():S14-5. PubMed ID: 15962526
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Cappuzzo F
J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
[No Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
